MEDI-545

BIOLOGICAL4 trials

Sponsors

MedImmune LLC, AstraZeneca

Conditions

DERMATOMYOSITIS OR POLYMYOSITISLupusLupus Erythematosus, SystemicSystemic Lupus Erythematosus

Phase 1

Safety and Tolerability of MEDI-545 in Patients Who Have Systemic Lupus Erythematosus (SLE)

CompletedNCT00299819

MedImmune LLCLupus

Start: 2006-03-31End: 2007-10-31Updated: 2007-12-18

A Study to Evaluate Safety of Multi-Dose MEDI-545 in Adult Patients With Dermatomyositis or Polymyositis

CompletedNCT00533091

MedImmune LLCDERMATOMYOSITIS OR POLYMYOSITIS

Start: 2008-04-30End: 2010-10-31Updated: 2012-05-28

Phase 2

A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus

CompletedNCT00657189

MedImmune LLCLupus, Lupus Erythematosus, Systemic

Start: 2008-07-31End: 2010-05-31Updated: 2016-08-09

A Study to Evaluate Safety and Tolerability of IV or SC Dose of MEDI-545 in Patients With Systemic Lupus Erythematosus.

CompletedNCT01031836

AstraZenecaSystemic Lupus Erythematosus

Start: 2009-11-25End: 2016-07-11Updated: 2018-11-19

Related Papers

Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study.

2011-07-27183 citations